type of ARF is acute respiratory distress syndrome (ARDS), 2 affecting 11-23% of intensive care unit (ICU) patients. 3 The incidence of ARF in ICU patients requiring mechanical ventilation ranges from 77.6/ 100.000 per year in Sweden, Denmark and Iceland 4 to 137.1/100.000 per year in Germany. 5 Outside the ICU an incidence of 784/100.000 per year has been reported. 6 In-hospital mortality rates from ARF ranges 21-41% in recent reports, 4, 6 depending on the underlying etiology, co-existing diseases and disease severity. 7 Hence, ARF is both a common and serious condition.
Description of the intervention
Therapeutic bronchoscopy with endobronchial washing and/or suctioning is used in critically ill patients with ARF to remove secretion, reinflate atelectasis and increase oxygenation. 8 It has been suggested that 47-75% of all bronchoscopies are performed for therapeutic purposes, [9] [10] [11] and some are both diagnostic and therapeutic. 8, 11, 12 Why is it important to do this review
The objective and potential benefits of therapeutic bronchoscopy include increased oxygenation and reduced respiratory work of breathing, 8, 11 while the potential harms include hypoxemia, bleeding, laryngo-and bronchospasm, and cardiovascular complications. 8, 11 The overall balance between the benefits and harms of therapeutic bronchoscopy is however unknown.
Consequently, we aimed to assess patientimportant benefits and harms of therapeutic bronchoscopy in critically ill patients with ARF. We hypothesized that the quantity and quality of evidence supporting the use of therapeutic bronchoscopy would be limited.
Methods
This systematic review with meta-analysis and trial sequential analysis (TSA) has been conducted according to the methodology of the Cochrane Collaboration 13 and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) working group. 14 The manuscript has been prepared according to the PRISMA (Preferred, Reporting Items for Systematic Reviews and Meta-Analysis) statement. 15 The protocol, including a statistical analysis plan, was published in the International Prospective Register of Systematic Reviews (PROSPERO, no. CRD420160 46235) prior to the conduct of the review. No deviations from this protocol have been made.
Research question
"Is therapeutic bronchoscopy superior to standard of care in critically ill patients with ARF?"
Eligibility criteria
We included randomized clinical trials (RCTs) assessing therapeutic bronchoscopy in adults and children with ARF (as defined by the original trials) in and outside the ICU, regardless of publication status, publication period, blinding and language. The intervention of interest was bronchoscopy (fiberoptic or rigid) with any type of washing or suctioning performed to improve the respiratory condition (therapeutic bronchoscopy), and the comparator was standard of care, including open and closed suctioning (no bronchoscopy).
We excluded non-RCTs (e.g. quasi-randomized trials, cross-over trials and observational studies), trials in animals, trials in neonates and trials in which bronchoscopy was performed for diagnostic purposes or for removal of foreign bodies or tumours.
Search strategy
We systematically searched the Cochrane Library (Issue 1, January 2017), MEDLINE (1946 onwards), EMBASE (1980 onwards) and Epistemonikos (Appendix S1). The search strategy was pilot-tested and refined before the final search was carried out. The latest search was performed June 28, 2017 . In addition, we handsearched reference lists of relevant trials and other systematic reviews. Unpublished trials were sought identified.
Study selection
Two authors (TM and KE) independently reviewed all titles and abstracts identified in the literature search, and excluded trials that were deemed obviously irrelevant. The remaining trials were evaluated in full-text. Disagreements were resolved with MHM.
Data extraction
Two authors (TM and KE) independently extracted data from each included trial using a data extraction form. The extracted information included trial characteristics (trial design, year of publication, trial duration and country), patient characteristics (inclusion-and exclusion criteria), type of intervention and comparator, the predefined outcome measures, and risk of bias. Authors were contacted for additional information; however none responded.
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Risk of bias assessment
Two authors (TM and KE) independently assessed the risk of systematic errors (bias) of the included trials, as recommended by the Cochrane collaboration. 13 The assessed domains included random sequence generation, allocation concealment, blinding of personnel and participants, blinding of outcome assessors, incomplete outcome data, selective outcome reporting and other bias including academic and financial bias. 20 If one or more domains were judged as high or unclear, the trial was classified as having an overall high risk of bias. 13 Disagreements were resolved with MHM.
Grade
The quality of evidence for each outcome was assessed according to GRADE. 14 The quality of evidence was downgraded for risk of bias, inconsistency, indirectness, imprecision and publication bias.
14 Accordingly, the quality of evidence was rated from "high" to "very low".
Outcome measures
Exclusively patient-important outcome measures were assessed. 21 The predefined primary outcome was all-cause mortality at longest follow-up. Secondary outcomes were: adverse events (as defined by the original trials), healthrelated quality of life at longest follow-up (as defined by the original trials), performance status (as defined by the original trials), duration (days) of mechanical ventilation, length of stay in hospital (days) and length of stay in ICU (days).
Statistical methods
We used Review manager 5.3 (the Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark), and the TSA program version 0.9.5.5 beta 22 to conduct conventional meta-analyses and trial sequential analysis (TSA), respectively.
For each included trial we estimated risk ratio (RR) with 95% confidence interval (CI) for dichotomous outcome measures, and mean difference (MD) with standard deviation (SD) for continuous outcome measures. Individual point estimates were subsequently summarized in conventional metaanalyses.
We quantified statistical heterogeneity between trials with inconsistency factor (I 2 ) and diversity (D 2 ) statistics. If I 2 was 0, we used and reported results from a fixed-effect model, and if I 2 > 0 we used and reported results from a random-effects model.
We conducted empirical continuity corrections in the zero event trials as a sensitivity analysis. The risk of random errors was assessed by TSA. TSA is a sample size calculation (interim analysis) for meta-analyses that widens the confidence intervals when data are too sparse to draw firm conclusions. 23 We applied trial sequential monitoring boundaries according to an a priori 20% relative risk difference (reduction or increase), alfa 5%, beta 90%, and a control event proportion suggested by the trials reporting the outcome in question. TSA adjusted CIs were estimated. In case less than 5% of the required information size had been accrued, no TSA graphics could be prepared.
The pre-planned analysis of small trial bias was cancelled because less than 10 trials were included.
Subgroup analyses
A number of predefined subgroup analyses were planned, but could not be carried out due to lack of data; (1) comparison of estimates from trials with low risk of bias vs. trials with high risk of bias (hypothesized direction of effect: increased intervention effect in trials with high risk of bias); (2) comparison of estimates from trials conducted in ICU patients vs. non-ICU patients (hypothesized direction of effect: increased intervention effect in ICU patients); (3) comparison of estimates from trials conducted in mechanically ventilated patients vs. non-mechanically ventilated patients (hypothesized direction of effect: increased intervention effect in mechanically ventilated patients); (4) Comparison of estimates from trials conducted in patients with atelectasis vs. pneumonia vs. aspiration vs. inhalational damage as etiology of ARF (hypothesized direction of effect: increased intervention effect in patients with aspiration and inhalational damage); (5) Comparison of estimates from trials assessing fiberoptic bronchoscopy vs. trials assessing rigid bronchoscopy (hypothesized direction of effect: increased intervention effect in patients receiving fiberoptic bronchoscopy). The following two subgroup analyses could be performed: (1) adults vs. children (hypothesized direction of effect: increased intervention effect in children); (2) medical vs. surgical patients (hypothesized direction of effect: increased intervention effect in medical patients).
We used Chi-square test to provide an indication of heterogeneity between trials (testof-interaction); P < 0.10 was considered statistically significant.
Results
Five trials comprising a total of 212 patients with ARF were included; [16] [17] [18] [19] 24 four trials could be included in the meta-analysis (n = 181). [17] [18] [19] 24 All trials were published in English. The main reasons for exclusion of trials were: (1) non-RCTs; (2) wrong intervention (e.g. bronchoscopy performed for diagnostic purposes); (3) wrong population; and (4) no relevant outcome data ( Fig. 1) .
Characteristics of trials
All trials included ICU patients. Two trials were conducted in Europe 17, 24 (n = 64) and one in Egypt 19 (n = 50) and Iran (n = 67), respectively. 18 Three trials were single-centre . 18, 19, 24 Details on the interventions and comparators are provided in Table 1 . In brief, two trials evaluated the effect of bronchoscopic lavage with saline irrigation, 18, 19 and two assessed the effect of lavage with a combination of saline and surfactant.
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Risk of bias
No trials were judged to have overall low risk of bias (Fig. 2) . The main reasons for high risk of bias were inadequate blinding, and selective and inadequate outcome reporting. Furthermore, one trial had potential financial bias. 20, 24 Outcome measures All-cause mortality Four trials (n = 181) provided information on all-cause mortality. [17] [18] [19] 24 The conventional meta-analysis showed no difference in allcause mortality between therapeutic bronchoscopy and standard of care (fixed effect: RR 0.34; 95% CI 0.12 to 1.00; P = 0.05; I 2 0%) (Fig. 3) . TSA highlighted that only 3% of the required information size of 5904 patients had been accrued in order to detect or reject a 20% relative risk difference (RRD). TSA adjusted CI was (RR 0.39; 95% CI 0.14 to 1.07; I 2 0%). Subgroup analyses were consistent with the primary estimate ( Table 2) .
Duration of mechanical ventilation
Two trials (n = 64) reported data on duration of mechanical ventilation. 17, 24 The conventional meta-analysis suggested a statistically significant reduced duration of mechanical ventilation in patients having therapeutic bronchoscopy as compared to standard of care (fixed effect: MD À6.74; 95% CI À8.05 to À5.43; P < 0.01; I 2 0%) ( Figure S1 ). TSA showed that only 42% of the required information size of 151 patients had been accrued in order to detect or reject a 20% RRD between the two groups. TSA adjusted CI was (MD À6.74; 95% CI À8.92 to À4.57; I 2 0%) ( Figure S3 ). Subgroup analyses were consistent with the primary estimate ( Table 2) .
Length of stay ICU
Three trials (n = 137) reported data on ICU length of stay. 18, 19, 24 The conventional metaanalysis suggested a statistically significant reduction in ICU length of stay in the bronchoscopy group (random effect: MD À4.50; 95% CI À7.10 to À1.90; P < 0.01; I 2 58%) ( Figure S2 ), however TSA could not confirm this (TSA adjusted MD À4.50; 95% CI À10.34 to 1.35; I 2 58%). Furthermore, TSA showed that only 24% of the required information size of 566 patients had been accrued in order to detect or reject a 20% RRD between the two groups ( Figure S4 ). Subgroup analyses were consistent with the primary estimate (Table 2) .
Other secondary outcome measures
The other predefined secondary outcome measures were not (or inadequately) reported.
Discussion
In this systematic review of RCTs comparing therapeutic bronchoscopy vs. standard of care (no bronchoscopy), we found very low quantity and quality of evidence supporting therapeutic bronchoscopy in critically ill patients with ARF.
Strengths and limitations
Strengths of our review include the methodology adhering to the recommendations of the Cochrane Collaboration 13 including a predefined published protocol and statistical analysis plan, a systematic literature search with no language restriction, independent and duplicate literature search, data extraction and risk of bias assessment, assessment of the risk of random errors using TSA, evaluation of patient-important outcome measures exclusively, 21 and assessment of the quality of evidence according to GRADE. 14 Our review has limitations. First, all trials had overall high risk of bias, which increases the risk of falsely inflated estimates. 25 Second, data on the majority of secondary outcomes were not available which challenges the interpretation and balance of the potential benefits and harms of therapeutic bronchoscopy. Third, the subgroup analyses that could be carried out included sparse data, which increases the risk of 26 Finally, we a priori considered a 20% RRD between groups clinically relevant. Consequently, smaller treatment effects cannot be ruled out.
Interpretation
All-cause mortality
The conventional meta-analysis showed no difference between patients receiving therapeutic bronchoscopy vs. no bronchoscopy. This result was consistent across sensitivity and subgroup analyses. Importantly, TSA highlighted that only 3% of the required information size had been accrued, indicating severe imprecision and very high risk of inflated estimates. 25 The quality of evidence was very low (downgraded for very serious risk of bias and very serious imprecision) ( Table 3) . As a result, no firm evidence for benefit or harm of therapeutic bronchoscopy on all-cause mortality in critically ill patients with ARF is available.
Duration of mechanical ventilation
The conventional meta-analysis suggested shorter duration of mechanical ventilation in patients undergoing therapeutic bronchoscopy as compared to standard of care. This was confirmed in the sensitivity analysis, and no difference in subgroup analyses was suggested. Importantly, TSA highlighted that only 42% of the required information size had been accrued, indicating imprecision and high risk of inflated estimates. 25 The quality of evidence was very low (downgraded for very serious risk of bias and serious risk of imprecision) (Table 3) . Consequently, the balance between the benefits and harms of therapeutic bronchoscopy on duration of mechanical ventilation in critically ill patients with ARF is unknown.
Length of stay, ICU
Conventional meta-analysis indicated a statistically significant reduced ICU length of stay in patients treated with therapeutic bronchoscopy. This was also suggested in sensitivity and subgroup analysis. Notably, TSA indicated that less than 25% of the required information size had been accrued, and the results of the conventional meta-analysis are therefore likely to overestimate the "true" effect. 25 The quality of evidence was very low (downgraded for very serious risk of bias and serious risk of imprecision) (Table 3) . Consequently, the suggested beneficial effect of therapeutic bronchoscopy on ICU length of stay is highly questionable.
Other secondary outcome measures Data on the remaining patient-important secondary outcome measures, including adverse events and quality of life were not available. The patient-important effects and safety of therapeutic bronchoscopy in critically ill patients with ARF therefore remains to be adequately assessed.
Relation to other reviews and implications for future research
No former systematic reviews of RCTs have assessed the balance between the benefits and *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI, Confidence interval; RR, Risk ratio; OR, Odds ratio; MD, Mean difference. GRADE Working Group grades of evidence. High quality: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. †All trials had very serious risk of bias based on the following: no trials were adequately blinded, the majority of trials were deemed high risk of reporting bias (selective outcome reporting) and one trial had risk of financial bias. ‡TSA highlighted that an estimated 3% of the required information size had been accrued (very serious imprecision). §TSA highlighted that an estimated 42% of the required information size had been accrued (serious imprecision). ¶TSA highlighted that an estimated 24% of the required information size had been accrued (serious imprecision). A number of conflicting narrative reviews have been published, 8, 11, 12, 27 however conclusions drawn from these reviews should be interpreted carefully, as all have serious limitations. None of the reviews published or registered a predefined protocol and statistical analysis plan, which increases the risk of bias, and is considered a key point in a trustworthy systematic review. 28 Most reviews did not use a systematic literature search, which also increases the risk of bias. Moreover, many reviews assessed nonpatient-important outcomes, including chest x-ray findings, airbronchograms and changes in PO2. Importantly, non-patient-important outcomes (surrogate outcomes) results in inflated estimates and increased risk of false positive findings. 21 Also, a number of observational studies and reviews thereof have evaluated the safety of bronchoscopy and bronchoalveolar lavage in critically ill patients. 8, 9, 11, 12, [29] [30] [31] The majority concluded that bronchoscopy is safe, with a low incidence of adverse events, including hypoxaemia, bleeding, laryngo-and bronchospasm, cardiovascular complications and post-bronchoscopic fever. 8, 9, 11, 12, [29] [30] [31] A review of observational studies reported an occurrence of adverse events in less than 10% (of which the majority were transient), and a very low mortality associated with therapeutic bronchoscopy (0.01-0.05%). 11 Importantly, we found no RCTs with detailed reporting of adverse events. As observational studies have inherent methodological limitations, including overestimation of beneficial effects and underestimation of harm, RCTs with meticulous assessment of adverse events are needed. 25 While neither the safety of therapeutic bronchoscopy nor its efficacy has been adequately and satisfactorily confirmed, the procedure is commonly used in daily clinical practice. 8 Informed decision-making about use of healthcare interventions relies on the validity of unbiased, balanced and objective data from high quality research. 32 Despite limited quantity and quality of evidence supporting an intervention, physicians may give the intervention anyway. The term "intervention bias" describes the likelihood of health care professionals to intervene when no intervention would be a reasonable alternative. 32 Reasons for this behaviour include clinical satisfaction when an intervention gives an impression of greater activity in patient care. 33 As a result, potentially futile or even harmful interventions may be adopted based on inadequate scientific evidence, e.g. observational data, low quality clinical trials and data from surrogate outcomes, if the alternative is not applying an intervention (watchful waiting). 32, 33 Use of therapeutic bronchoscopy may be an example of intervention bias.
Conclusion
The quantity and quality of evidence supporting therapeutic bronchoscopy in critically ill patients with ARF is very low with no firm evidence for benefit or harm. To ensure patient safety, it is important to balance the benefits and harms of therapeutic bronchoscopy before using it as routine in everyday clinical practice. Figure S1 . Therapeutic bronchoscopy versus standard of care (no bronchoscopy) and the effect on duration of mechanical ventilation. Size of squares for relative risk (RR) reflects the weight of the trial in pooled analyses, horizontal bars 95% confidence interval (CI). Figure S2 . Therapeutic bronchoscopy versus standard of care (no bronchoscopy) and the effect on length of stay in ICU. Size of squares for relative risk (RR) reflects the weight of the trial in pooled analyses, horizontal bars 95% confidence interval (CI). Figure S3 . Trial sequential analysis of duration of mechanical ventilation (2 trials, n=64). The upper and lower red boundaries are trial sequential monitoring boundaries for benefit and harm. A diversity adjusted information size of 151 patients was calculated using a = 0.05 (two sided), b = 0.10 (power 90%), D 2 = 0%, and an anticipated relative risk difference of 20%. The blue cumulative z curve, constructed using a random effects model reached the trial sequential monitoring boundaries for benefit and harm, indicating that a 20% relative risk difference may be present between the two groups. However, only 42% of the required information size of 151 patients had been accrued. In conclusion, TSA highlights that (too) few patients have been included with resulting high risk of random errors and a false positive finding (low certainty that this is the true effect). Figure S4 . Trial sequential analysis of duration of length of stay in ICU (2 trials, n=137). The upper and lower red boundaries are trial sequential monitoring boundaries for benefit and harm. A diversity adjusted information size of 566 patients was calculated using a = 0.05 (two sided), b = 0.10 (power 90%), D 2 = 0%, and an anticipated relative risk difference of 20%. The blue cumulative z curve, constructed using a random effects model did not reach the trial sequential monitoring boundaries for benefit and harm, rendering evidence of difference in effect between groups inconclusive. Only 24% of the required information size of 566 patients had been accrued. In conclusion, TSA highlights that (too) few patients have been included with resulting high risk of random errors and a false positive finding (low certainty that this is the true effect).
